Ultrasound is more reliable than inflammatory parameters to evaluate disease activity in patients with RA receiving tocilizumab therapy

The target of treatment for rheumatoid arthritis (RA) is to keep low disease activity or remission. Tocilizumab can fully inhibit interleukin-6 and C reactive protein (CRP) production. The goal of the study is to search whether tocilizumab treatment compared with adalimumab treatment had the similar...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Wen-Chan, Lai, Han-Ming, Ko, Chi-Hua, Chen, Jia-Feng, Hsu, Chung-Yuan, Chen, Ying-Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073910/
https://www.ncbi.nlm.nih.gov/pubmed/29581384
http://dx.doi.org/10.1136/jim-2017-000705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073910/
https://www.ncbi.nlm.nih.gov/pubmed/29581384
http://dx.doi.org/10.1136/jim-2017-000705

Ejemplares similares